Browse GRIA1

Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Endoplasmic reticulum membrane Multi-pass membrane protein Cell junction, synapse, postsynaptic cell membrane Multi-pass membrane protein Cell junction, synapse, postsynaptic cell membrane, postsynaptic density Multi-pass membrane protein Cell projection, dendrite Cell projection, dendritic spine Early endosome membrane Multi-pass membrane protein Recycling endosome membrane Multi-pass membrane protein Note=Interaction with CACNG2, CNIH2 and CNIH3 promotes cell surface expression. Colocalizes with PDLIM4 in early endosomes. Displays a somatodendritic localization and is excluded from axons in neurons (By similarity).
Domain PF01094 Receptor family ligand binding region
PF00060 Ligand-gated ion channel
PF10613 Ligated ion channel L-glutamate- and glycine-binding site
Function

Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate.

> Gene Ontology
 
Biological Process GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006898 receptor-mediated endocytosis
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0007215 glutamate receptor signaling pathway
GO:0007611 learning or memory
GO:0007613 memory
GO:0007616 long-term memory
GO:0016050 vesicle organization
GO:0031623 receptor internalization
GO:0035235 ionotropic glutamate receptor signaling pathway
GO:0043112 receptor metabolic process
GO:0044708 single-organism behavior
GO:0048167 regulation of synaptic plasticity
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0050804 modulation of synaptic transmission
GO:0050805 negative regulation of synaptic transmission
GO:0050890 cognition
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0060292 long term synaptic depression
GO:0090114 COPII-coated vesicle budding
Molecular Function GO:0004970 ionotropic glutamate receptor activity
GO:0004971 AMPA glutamate receptor activity
GO:0005216 ion channel activity
GO:0005230 extracellular ligand-gated ion channel activity
GO:0005231 excitatory extracellular ligand-gated ion channel activity
GO:0005234 extracellular-glutamate-gated ion channel activity
GO:0008066 glutamate receptor activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022824 transmitter-gated ion channel activity
GO:0022834 ligand-gated channel activity
GO:0022835 transmitter-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0030165 PDZ domain binding
GO:0030594 neurotransmitter receptor activity
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0008021 synaptic vesicle
GO:0008328 ionotropic glutamate receptor complex
GO:0012507 ER to Golgi transport vesicle membrane
GO:0014069 postsynaptic density
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030139 endocytic vesicle
GO:0030424 axon
GO:0030425 dendrite
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032281 AMPA glutamate receptor complex
GO:0032589 neuron projection membrane
GO:0032590 dendrite membrane
GO:0032591 dendritic spine membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0033267 axon part
GO:0034702 ion channel complex
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0043235 receptor complex
GO:0044297 cell body
GO:0044308 axonal spine
GO:0044309 neuron spine
GO:0045211 postsynaptic membrane
GO:0055037 recycling endosome
GO:0060076 excitatory synapse
GO:0070382 exocytic vesicle
GO:0097060 synaptic membrane
GO:0098793 presynapse
GO:0098794 postsynapse
GO:0098802 plasma membrane receptor complex
GO:0098878 neurotransmitter receptor complex
GO:0099503 secretory vesicle
GO:0099572 postsynaptic specialization
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04024 cAMP signaling pathway
hsa04080 Neuroactive ligand-receptor interaction
hsa04713 Circadian entrainment
hsa04720 Long-term potentiation
hsa04723 Retrograde endocannabinoid signaling
hsa04724 Glutamatergic synapse
hsa04728 Dopaminergic synapse
hsa04730 Long-term depression
Reactome R-HSA-399710: Activation of AMPA receptors
R-HSA-442755: Activation of NMDA receptor upon glutamate binding and postsynaptic events
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-597592: Post-translational protein modification
R-HSA-6794362: Protein-protein interactions at synapses
R-HSA-8849932: SALM protein interactions at the synapses
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-416993: Trafficking of GluR2-containing AMPA receptors
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-438066: Unblocking of NMDA receptor, glutamate binding and activation
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GRIA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GRIA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GRIA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.010.963
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1960.702
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1290.775
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7560.261
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.2140.372
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1960.885
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.9730.0339
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.7020.269
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-2.2870.169
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0720.859
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1430.816
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3410.235
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GRIA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.110.20.91
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211733.317.615.70.46
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.827.33.51
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.911.1-3.20.686
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.521.4-8.90.642
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRIA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRIA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRIA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRIA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GRIA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GRIA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGRIA1
Nameglutamate receptor, ionotropic, AMPA 1
Aliases GluA1; GLURA; GLUR1; GLUH1; HBGR1; AMPA 1; AMPA-selective glutamate receptor 1; gluR-1; gluR-A; gluR-K1; Glu ......
Chromosomal Location5q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GRIA1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GRIA1.
ID Name Drug Type Targets #Targets
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69
DB00228EnfluraneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GAB ......23
DB00753IsofluraneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GAB ......22
DB00898EthanolSmall MoleculeCACNA1C, CACNA1D, CACNA1S, CACNB1, CACNG1, CACNG2, CHRNA10, CHRNA2 ......52
DB01028MethoxyfluraneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GAB ......23
DB01189DesfluraneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GAB ......22
DB01236SevofluraneSmall MoleculeATP2C1, ATP5D, GABRA1, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GAB ......23
DB04982TalampanelSmall MoleculeGRIA1, GRIA2, GRIA3, GRIA44
DB05047CX717Small MoleculeBDNF, GRIA1, GRIA2, GRIA3, GRIA45
DB06247CX516Small MoleculeGRIA11
DB08883PerampanelSmall MoleculeGRIA11
DB09289TianeptineSmall MoleculeGRIA1, HTR1A, SLC6A43
DB13146Fluciclovine (18F)Small MoleculeGRIA1, GRIA2, GRIA3, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, ......14